Partnering Companies
Millennium-Takeda: A nimble biotech with a global footprint
“We see partnering as an integral part of building the business for the long term, and you can think of our business development efforts for partnering as building an external R&D engine,” said Anna Protopapas.
Partnering People
Merck Serono Venture Fund: Fresh funding for early stage deals
In what has proven to be a turbulent period for the biotech industry since Merck Serono launched its corporate venture fund in March, one deal has been announced, and Bulthuis hinted he may have news to discuss at BIO-Europe 2009 when he participates in the panel discussion “Funding Early Stage Programs in Difficult Times.” Read more »
Daphne Zohar gathers a blue-ribbon panel of dealmakers for BioPharm America in Boston to focus on unexpected dynamics that can derail high profile transactions. In this interview, she provides fresh perspectives that challenge conventional views of partnering and describes the trail-blazing strategy of her firm, PureTech Ventures.
Ahead of BioPharm America 2010 in Boston, Nycomed’s lead dealmaker, Kerstin Valinder, offers an in-depth discussion of partnering that jumps to the top of our ‘Summer Reading’ list. In this exclusive interview with partneringNEWS she traces the company’s spectacular growth to EUR 3 billion in sales, outlines Nycomed’s targets for further growth, and shares fresh views on how the ‘professionalization’ of partnering changes business development.
The leading event for partnering in life sciences in Scandinavia, BioTech Forum this year is being held in concert with the landmark event ScanLab. Together these events will draw more than 6,000 participants to the Bella Center, September 28–30, 2010.
As dealmaking reaches a peak in life sciences for 2010, BioPharm America™ presents an unrivalled opportunity to help companies raise capital, form licensing agreements, and enter co-development deals.
“We see partnering as an integral part of building the business for the long term, and you can think of our business development efforts for partnering as building an external R&D engine,” said Anna Protopapas.
“Effective partnering is all about target marketing, which means having an in-depth and multi-dimensional view of your prospective partners’ needs. For the most part when biotech companies use an online web-enabled partnering system they employ an opposite approach—a mass marketing approach to partnering.”
“In the life science industry, there are purely scientific meetings, and then there are pure dealmaking events, yet intelligent business development requires elements of both,” said Ed Saltzman.
An unparalleled opportunity for close collaboration among medtech decision makers and investors, EuroMedtech attracts companies from all parts of the advanced medical technology industry, including diagnostics, imaging, orthopedics, cardiovascular, biomaterials and eHealth technologies.
Hot Companies
Newsletter